Durec­t's non-opi­oid painkiller brush­es aside check­ered past, gain­ing FDA ap­proval in shoul­der surg­eries

Af­ter a long and of­ten bumpy ride, Durect’s non-opi­oid painkiller has re­ceived the FDA’s en­dorse­ment.

US reg­u­la­tors ap­proved the sus­tained-re­lease bupi­va­caine so­lu­tion for use up to 72 hours af­ter cer­tain shoul­der surg­eries, Durect an­nounced Tues­day morn­ing. The drug is called Posimir, and its ap­proval breathes life in­to a com­pa­ny that once teetered on pen­ny stock ter­ri­to­ry af­ter the pro­gram racked up two tri­al fail­ures and a CRL.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER